Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Steven Wagner
University of California, San Diego, Department: Neurosciences
Should you be removed from our database? Contact us at [email protected]. Read more below.
Neurogenetic Pharmaceuticals, Inc
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Wagner is a co-founder of NeuroGenetic Pharmaceuticals, Inc. (NeuroGenetic) and holds equity interest. NeuroGenetic is developing NGP555, a ƴ-secretase modulator (GSM), for Alzheimer’s disease. Dr. Wagner is a co-investigator and will oversee measurement of αβ levels in brain, plasma and cerebrospinal fluid (CSF). In mouse models of Alzheimer disease in Down syndrome (AD-DS), this project is to test the therapeutic hypothesis that GSM BPN15606 will reduce the level of C99 and αβ42 to prevent and/or lessen neurodegeneration.
Treating with Gamma-Secretase Modulators to Prevent Neurodegeneration in Mouse Models of Down Syndrome and Alzheimer Disease
Narrative: An extra copy of the gene for APP is necessary for Alzheimer disease (AD) in Down syndrome (DS); the APP products responsible include the 99 residue C-terminal fragment (C99) and A?42. Increased C99 and A?42 are present in mouse models of DS and of AD. To reduce C99 and A?42, and prevent or lessen neurodegeneration, we will treat with the ?-secretase modulator (GSM) BPN15606, a small molecule that increases ?-secretase activity and that lessened neurodegeneration in preliminary studies.
Filed on June 20, 2018.
Tell us what you know about Steven Wagner's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Steven Wagner”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Steven Wagner | University of California, San Diego | Conflict of Interest | Neurogenetic Pharmaceuticals, Inc. | $0 - $4,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.